ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2012
Expressions of Osteopontin (OPN), ανβ3 and Pim-1 Associated with Poor Prognosis in Non-small Cell Lung Cancer (NSCLC).
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis.Journal of molecular histology · 2014Pooled it
- Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.Frontiers in oncology · 2021Review
- Review
- Expression of PIM-1 in salivary gland adenoid cystic carcinoma: Association with tumor progression and patients' prognosis.Oncology letters · 2018Article
- Osteopontin promotes cancer cell drug resistance, invasion, and lactate production and is associated with poor outcome of patients with advanced non-small-cell lung cancer.OncoTargets and therapy · 2018Article
- Article
- Roles of osteopontin and matrix metalloproteinase-7 in occurrence, progression, and prognosis of nonsmall cell lung cancer.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2015Article
- RNA-seq analysis of lung adenocarcinomas reveals different gene expression profiles between smoking and nonsmoking patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection.Journal of cancer research and clinical oncology · 2015Article
- Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma.Journal of experimental & clinical cancer research : CR · 2014Article
- Genetic association of osteopontin (OPN) and its receptor CD44 genes with susceptibility to Chinese gastric cancer patients.Journal of cancer research and clinical oncology · 2014Article
- Osteopontin promoter polymorphisms at locus -443 are associated with metastasis and poor prognosis of human intrahepatic cholangiocarcinoma in Chinese population.International journal of clinical and experimental pathology · 2014Article
- OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC.International journal of genomics · 2014Article
- Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis.Journal of experimental & clinical cancer research : CR · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the expressions of osteopontin (OPN), (α) (ν) (β) (3) and Pim-1 in non-small cell lung cancer (NSCLC), and investigate their potential pathogenic roles in the development of NSCLC.
methodsImmunohistochemistry was used to examine the expressions of OPN, (α) (ν) (β) (3) and Pim-1 in cohort (136 cases) of NSCLC samples and their adjacent normal lung tissue specimens. Statistical analysis was performed to evaluate the relationships among expressions of OPN, (α) (ν) (β) (3) and Pim-1 and their associations with patients clinico- pathological parameters.
resultsThe expressions of OPN and Pim-1 were predominantly observed in cytoplasm. The expression of (α) (ν) (β) (3) was mostly detected in cytoplasm and/or membrane. In NSCLC samples, the positive rates of OPN, (α) (ν) (β) (3) and Pim-1 expressions were 68.4% (93/136), 77.2% (105/136) and 57.4% (78/136), respectively. In normal lung tissues, in contrast, the positive rates of OPN, (α) (ν) (β) (3) and Pim-1 were 24.0% (12/50), 26.0% (13/50) and 16.0% (8/50), respectively. There were significant differences of the positive expression rates of OPN, (α) (ν) (β) (3) and Pim-1 between NSCLCs samples and normal lung tissues (P<0.01). In addition, the positive expression of OPN, (α) (ν) (β) (3) and Pim-1 in NSCLCs samples was significantly associated with increased pathological grade, lymph node metastasis and advanced clinical stage (P<0.01), and they were independent of other clinicopathological parameters (P>0.05). Furthermore, a significantly positive correlation between the expression of OPN and (α) (ν) (β) (3) (r=0.38, P<0.01), OPN and Pim-1 (r=0.37, P<0.01), or (α) (ν) (β) (3) and Pim-1 (r=0.20, P<0.05) was evaluated in our NSCLC cohort.
conclusionOPN, (α) (ν) (β) (3) and Pim-1 proteins are frequently overexpressed in NSCLC, and they may play important roles in the development and/or progression of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.